Abstracts & Posters
IASP 2020
Beyond the Numbers: A Validations Study of the Pain Tolerability Question
JOA 2020
Efficacy of Tanezumab, a Nerve Growth Factor Antibody, in Japanese Patients With Chronic Low Back Pain: A 56-Week Treatment, Celecoxib-Controlled, Study
EULAR 2020
Efficacy of Subcutaneous Tanezumab for the Treatment of Chronic Low Back Pain: An Analysis of Brief Pain Inventory-Short Form Scores from a Randomized, Placebo- and Tramadol-Controlled, Phase 3 Trial
AAN 2020
Subcutaneous Tanezumab Versus Placebo or Tramadol in Patients with Chronic Low Back Pain: 16-Week Efficacy and Safety Results from a Phase 3 Study
NeuPSIG 2019
Assessment of the Efficacy and Safety of Vixotrigine in Participants With Lumbosacral Radiculopathy: Results of a Randomized, Placebo-Controlled Trial
EFIC 2019
Subcutaneous Tanezumab Versus Tramadol for Chronic Low Back Pain: Efficacy and Safety Results From a 56-Week Phase 3 Study With a 24-Week Follow Up Period
SURF 2014
Analysis of Recruitment Methods in an Analgesic Clinical Trial
APS 2014
Interpretation of Urine Drug Testing Results in Patients Using Transdermal Buprenorphine Preparations for the Treatment of Chronic Non-Cancer Pain
IASP 2013
Lumbar Stenosis Outcomes Research (Lustor II)
TPR 2012
A Randomized, Single-site, Two-period, Crossover Trial Comparing Pregabalin With Active Placebo for the Treatment of Neurogenic Claudication Associated With Lumbar Stenosis (Lustor I)
AAPM 2012
Identification of Key Gaps in Opioid Prescriber Knowledge With an Industry-Sponsored REMS Credentialing Test
AAPM 2011
A Preliminary Study of the Role of Neuropathic Screening Tools as Predictors of Response to a Trial of Spinal Cord Stimulation in Patients with Post Laminectomy Pain Syndrome
AAN Poster 2011
Validation of Patient Reported Outcome Endpoints for Nonsurgical Treatment of Lumbar Spinal Stenosis
ANNS & CNS Digital Poster 2010
Key Limitation of Functional Assessment by treadmill Testing in Patients with Lumbar Spinal Stenosis
AAN Poster 2009
Development of Novel Clinical Trial Endpoint for Neurogenic Intermittent Claudication